Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455748 | 0.79 | HRH4 (0.50) | HRH4HRH3SCN8AALDH1A1S1PR1 | |
| SCHEMBL14415405 | 0.78 | ALDH1A1 (0.53) | HRH4HRH3SCN8ATMEM97KCNH2 | |
| SCHEMBL16443930 | 0.77 | HRH4 (0.63) | HRH4HRH3SCN8AALDH1A1MEN1 | |
| SCHEMBL14420391 | 0.76 | HRH4 (0.56) | HRH4HRH3SCN8ATMEM97KCNH2 | |
| SCHEMBL4423057 | 0.76 | SCN8A (0.51) | HRH4HRH3SCN8ATMEM97KCNH2 | |
| SCHEMBL27881905 | 0.76 | HRH4 (0.45) | HRH4HRH3SCN8ATMEM97KCNH2 | |
| SCHEMBL3456757 | 0.76 | MCHR1 (0.48) | HRH4HRH3SCN8AALDH1A1MEN1 | |
| SCHEMBL14021244 | 0.75 | HRH4 (0.50) | HRH4HRH3SCN8ATMEM97KCNH2 | |
| SCHEMBL13598369 | 0.75 | SMN1; SMN2 (0.49) | HRH4HRH3TMEM97KCNH2ALDH1A1 | |
| SCHEMBL3960489 | 0.75 | SCN8A (0.58) | HRH4HRH3SCN8ATMEM97KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-7638520-B2 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1686119-B1 | Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | SMITHKLINE BEECHAM P.L.C. | 2009-07-02 | — | — | US | disclosed |
| US-7470694-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-30 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1686119-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1263740-B1 | PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-6649619-B1 | 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl) benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimeth ylenepyrimidin-4-one or salt; lipoprotein-associated phospholipase A inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | PLA2G4A, PLA2G4B, PLA2G1B | HRH4 1213/4885HRH3 2365/4885SCN8A 4748/4885 |
| US-20150045375-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | HRH4 1850/4885HRH3 2622/4885SCN8A 4765/4885 |
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | HRH4 1850/4885HRH3 2622/4885SCN8A 4765/4885 |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | HRH4 939/4885HRH3 1992/4885SCN8A 3999/4885 |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | PLA2G7, PLAT, PLA2G1B | HRH4 873/4885HRH3 1346/4885SCN8A 4208/4885 |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | HRH4 1213/4885HRH3 2365/4885SCN8A 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.